Journal
FRONTIERS IN PHARMACOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.796590
Keywords
diammonium glycyrrhizinate; obesity; gut microbiota; bile acids; farnesoid X-activated receptor
Categories
Funding
- National Natural Science Foundation of China [82070545]
- Key Project of Science and Technology Pillar Program of Tianjin [20YFZCSY00020]
- TianQing Liver disease research fund [TQGB20190103]
- Tianjin Research Innovation Project for Postgraduate Students [2020YJSS175]
Ask authors/readers for more resources
DG treatment suppressed microbes associated with BSH activity, increased taurine-conjugated BAs, and inhibited ileal FXR-FGF15 signaling, leading to improvements in obesity-related metabolism. This demonstrates the potential for a novel approach in the treatment of obesity by targeting gut microbiota-conjugated BAs-FXR axis.
Obesity is a worldwide epidemic metabolic disease. Gut microbiota dysbiosis and bile acids (BAs) metabolism disorder are closely related to obesity. Farnesoid X-activated receptor (FXR), served as a link between gut microbiota and BAs, is involved in maintaining metabolic homeostasis and regulating glucose and lipid metabolism. We previously reported that diammonium glycyrrhizinate (DG) could alter gut microbiota and prevent non-alcoholic fatty liver disease. However, it remains ambiguous how DG affects the gut microbiota to regulate host metabolism. In this present study, 16S rRNA Illumina NovaSeq and metabolomic analysis revealed that DG treatment suppressed microbes associated with bile-salt hydrolase (BSH) activity, which, in turn, increased the levels of taurine-conjugated BAs accompanied by inhibition of ileal FXR-FGF15 signaling. As a result, several obesity-related metabolism were improved, like lower serum glucose and insulin levels, increased insulin sensitivity, few hepatic steatosis and resistance to weight gain. Additionally, decreased level of serum lipopolysaccharide was observed, which contributed to a strengthened intestinal barrier. The effect of DG on weight loss was slightly enhanced in the antibiotics-treated obese mice. Collectively, the efficacy of DG in the treatment of obesity might depend on gut microbiota-conjugated BAs-FXR axis. Hence, it will provide a potential novel approach for the treatment of obesity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available